Search alternatives:
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
significant amount » significant impact (Expand Search)
amount decrease » point decrease (Expand Search)
reported case » reported cases (Expand Search), reported use (Expand Search), imported cases (Expand Search)
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
significant amount » significant impact (Expand Search)
amount decrease » point decrease (Expand Search)
reported case » reported cases (Expand Search), reported use (Expand Search), imported cases (Expand Search)
-
41
DataSheet_2_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx
Published 2021“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”
-
42
DataSheet_6_Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.docx
Published 2021“…</p>Conclusions<p>This case series reports the significant therapeutic effect of pyrotinib on cutaneous metastases of HER2-positive BC for the first time. …”
-
43
-
44
-
45
-
46
-
47
-
48
Case outcomes, signs, and symptoms from electronically reported RMSF cases, 2011–2019.
Published 2022Subjects: -
49
Distribution of the amount of physical activity recorded during head-raising movements.
Published 2025Subjects: -
50
-
51
-
52
-
53
-
54
-
55
Image_1_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.tif
Published 2022“…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
-
56
-
57
-
58
-
59
-
60